secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001599298-25-000156
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit plans BLA for ivonescimab in Q4 2025; HARMONi-6 meets endpoint
---------------------------------------------------------------------

- Plans to submit BLA for ivonescimab plus chemotherapy in EGFRm NSCLC in Q4 2025 based on HARMONi study.
- HARMONi-6: ivonescimab + chemo reduced risk of progression/death by 40% vs tislelizumab+chemo in 1L squamous NSCLC (HR=0.60, p<0.0001).
- HARMONi-3 split into squamous and non-squamous analyses; squamous enrollment completion expected H1 2026, data H2 2026.
- New global Phase III HARMONi-GI3 in 1L CRC initiated; targets 600 patients, PFS primary endpoint.
- Q3 2025 GAAP net loss $231.8M ($0.31/sh), non-GAAP net loss $101.0M ($0.13/sh); cash $238.6M at Sept 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000156/0001599298-25-000156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000156/smmt-20251017.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer